Updated:
Burroughs Wellcome Fund
The Burroughs Wellcome Fund was established in 1955 as the philanthropic arm of the pharmaceutical company founded by Henry Wellcome and Silas Burroughs.
Burroughs Wellcome Fund
The Burroughs Wellcome Fund was established in 1955 as the philanthropic arm of the pharmaceutical company founded by Henry Wellcome and Silas Burroughs. It became an independent private foundation in 1993 after receiving a $400 million endowment transfer from the Wellcome Trust. The organization focuses exclusively on advancing biomedical sciences through peer-reviewed grants that support researchers at critical career stages. The fund allocates across private equity, hedge funds, private credit, and venture capital strategies while maintaining a tactical portfolio of public equities and bonds. Confirmed limited-partner positions include Hamilton Lane Advisors, Dyal Capital, Neuberger Berman, Intersouth Partners, and Harbourvest. Geographic exposure centers on North America with additional holdings in European public markets such as Intesa Sanpaolo and UniCredit. Grant programs extend to institutions in the United States and Canada. Assets total $785 million. The foundation employs no disclosed investment staff count and operates from a single headquarters in Research Triangle Park, North Carolina. It maintains memberships in the Council on Foundations and Health Research Alliance. January 2024 marked the launch of its Climate + Health Excellence Centers initiative, which funds interdisciplinary research on climate impacts on human health. The foundation's structure separates grantmaking from investment operations through a dedicated investment committee chaired by Michael Giarla. This separation allows the endowment to pursue returns from external managers while the grant programs remain mission-directed and independent of investment performance.
General information
Firm type
Endowment / Foundation
Year founded
1955
Location
Region
North America
Country
United States
City
Durham
Corporate office
21 T.W. Alexander Drive, Research Triangle Park, NC 27713-2847, United States
Principals
Louis J. Muglia
President and CEO
Jenny Ting
Chair of the Board of Directors
Michael Giarla
Board Member and Investment Committee Chair
Sector focus
Frequently asked questions
Who runs investment decisions at Burroughs Wellcome Fund?
Michael Giarla chairs the Investment Committee. The foundation uses external advisors including Hamilton Lane Advisors, Blackrock Alternative Advisors, and Neuberger Berman for manager selection and oversight.
Does Burroughs Wellcome Fund participate in fund commitments or only direct deals?
The fund acts primarily as a limited partner in private equity, venture, and hedge fund vehicles. Holdings include commitments to Hamilton Lane Private Equity and Private Debt Funds, Dyal Capital Private Equity Funds, and Intersouth Partners VI.
Where does the underlying wealth come from?
The endowment originated from the pharmaceutical business founded by Henry Wellcome and Silas Burroughs. Independence was achieved in 1993 via a $400 million gift from the Wellcome Trust.
What investment stages does Burroughs Wellcome Fund typically target?
Through its external managers the fund gains exposure to buyout, growth, early-stage venture, and special situations strategies. Direct grant activity focuses on early-career biomedical researchers rather than company stages.
How is Burroughs Wellcome Fund related to Wellcome Trust?
The fund began as the U.S. corporate foundation of Burroughs Wellcome Co. and became fully independent in 1993 after receiving a $400 million endowment from the Wellcome Trust.
Does Burroughs Wellcome Fund maintain philanthropic structures, and how are they separated?
All activities operate under the single foundation entity. Grantmaking and investment functions are divided internally with separate oversight by the Board and Investment Committee.
What is Burroughs Wellcome Fund's known posture on co-investments alongside external GPs?
The fund invests exclusively through fund commitments and does not execute direct co-investments. All private-market exposure flows through limited-partner interests in third-party vehicles.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: